Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003313 · ClinicalTrials.gov registry record · Phase 3
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 243
- Enrollment target
NCT00003313: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00003313 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 243 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003313, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 243 participants
- Enrollment target
Study Summary
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- BIOLOGICAL filgrastim
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 1998-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00003313 record still lists
NCT00003313 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003313 about?
NCT00003313 is a clinical study titled "Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer". RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III tri...
What is the current status of trial NCT00003313?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 1998-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00003313?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), filgrastim (BIOLOGICAL), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003313?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003313's enrollment target sits among peer trials
243 1269th of 2000 higher than 731 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia